N-[2-(3-氨基-4-甲氧基苯基)乙基]-2,2,2-三氟乙酰胺 | 81654-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: N-[2-(3-氨基-4-甲氧基苯基)乙基]-2,2,2-三氟乙酰胺
• 英文名称: N-[2-(3-amino-4-methoxyphenyl)ethyl]-2,2,2-trifluoro acetamide
• 英文别名: N-<2-(3-amino-4-methoxyphenyl)ethyl>-2,2,2-trifluoroacetamide；N-(3-amino-4-methoxyphenethyl)-2,2,2-trifluoroacetamide；2-methoxy-5-(2-trifluoroacetamidoethyl)aniline；N-[2-(3-amino-4-methoxyphenyl)ethyl]trifluoroacetamide；N-[2-(3-amino-4-methoxyphenyl)ethyl]-2,2,2-trifluoroacetamide
• CAS: 81654-49-1
• 化学式: C₁₁H₁₃F₃N₂O₂
• 分子量: 262.232
• InChiKey: YWJWLNVEAPUKNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[2-(3-氨基-4-甲氧基苯基)乙基]-2,2,2-三氟乙酰胺 在 盐酸 作用下， 以 二苯醚 为溶剂， 反应 1.5h， 生成 5-(2-trifluoroacetamidoethyl)-8-methoxy-4-quinolone
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of tyramine congeners containing fused heterocyclic rings

  摘要：

  A series of tyramine congeners carrying a fused heterocyclic ring were synthesized with the aim of combining the positive inotropic effect of the cardiac phosphodiesterase III inhibitors with the vasodilatory effect of heterocyclic dopamine receptor agonists. None of the compounds showed the desired combination of properties. 2-Ethoxycarbonyl-4-(2-aminoethyl)-7-hydroxyindole 24 elicited a marked hypotensive effect in spontaneously hypertensive rats.

  DOI：

  10.1016/0223-5234(93)90018-a
• 作为产物：
  描述：

  N-<2-(4-methoxy-3-nitrophenyl)ethyl>-2,2,2-trifluoroacetamide 在 镍 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以76.3%的产率得到N-[2-(3-氨基-4-甲氧基苯基)乙基]-2,2,2-三氟乙酰胺
  参考文献：
  名称：

  4-（2-氨基乙基）-2（3H）-吲哚酮及相关化合物作为外围结前多巴胺受体激动剂的合成及体外评价。

  摘要：

  合成了一系列（β-氨基乙基）吲哚酮和相关化合物，并在体外刺激的离体灌流兔耳动脉中作为外围结前多巴胺能激动剂进行了体外评估。4- [2-（二-正丙基氨基）乙基] -7-羟基-2（3H）-吲哚酮是测试的最有效化合物（ED50 = 2 +/- 0.3 nM），而相关的仲胺24和des-OH衍生物28和34的效力略低。使用4-甲氧基苯乙胺和2-甲基-3-硝基苯基乙酸作为合成4-（β-氨基乙基）吲哚酮的起始原料。通过硝化衍生自4-甲氧基苯基乙酸的苯乙胺43制备开环的3-酰基氨基类似物46和47。非活性异构体吲哚酮38、39和41衍生自4-硝基苯乙胺和吲哚酮-6-乙酸。

  DOI：

  10.1021/jm00156a010

文献信息

• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。
• [EN] AMINE COMPOUNDS<br/>[FR] DERIVES D'INDOLE SERVANT D'ANTAGONISTE DE SOMATOSTATINE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004046107A1

  公开（公告）日：2004-06-03

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种公式(I)的化合物，其中环A代表一个具有可选取代基的芳香环；B、Y和Ya相同或不同，分别代表一个键等；R1和R2相同或不同，每个代表一个氢原子等；R3代表一个氢原子等；R4和R5相同或不同，每个代表一个氢等；R6代表一个可选有取代基的吲哚基团；Z和Za相同或不同，每个代表一个氢原子等；或其盐或前药，具有生长抑素受体结合抑制活性，并且用于预防或治疗与生长抑素相关的疾病。
• Compounds
  申请人：Fisons plc

  公开号：US04657929A1

  公开（公告）日：1987-04-14

  There are provided pharmaceutical compounds useful in treating hypertension, heart diseases and renal failure. These compounds are 4-hydroxy phenethylamines wherein the 3 position on the phenyl nucleus is occupied by either an amino, amide, carbamyl, urea sulfonamide, substituted alkyl or fluorine atom, and the amine group is further linked to another phenyl radical through an alkylene radical which may contain nitrogen, oxygen, sulfur or cyclic hydrocarbon radicals as intervening groups.

  提供了药物化合物，可用于治疗高血压、心脏疾病和肾功能衰竭。这些化合物是4-羟基苯乙胺，其中苯环上的3位置被氨基、酰胺、氨基甲酰、脲磺酰胺、取代烷基或氟原子占据，并且胺基进一步通过含有氮、氧、硫或环烃基团的烷基团与另一个苯基团连接。
• Para ethyl amino phenol pharmaceutical compounds
  申请人：Fisons plc

  公开号：US04791216A1

  公开（公告）日：1988-12-13

  There are provided paraethylamine phenol compounds of formula I, ##STR1## and pharmaceutically acceptable derivatives thereof. There are also described the use of the compounds of formula I as pharmaceuticals, methods for making the compounds and pharmaceutical, e.g. cardiac, compositions containing the compounds.

  提供了公式I的对位乙基苯酚化合物，## STR1 ##和其药学上可接受的衍生物。还描述了公式I化合物作为药物的用途，制备化合物和药物（例如心脏）组合物的方法。
• Indole derivatives as somatostatin agonists or antagonists
  申请人：Abe Hidenori

  公开号：US20060223826A1

  公开（公告）日：2006-10-05

  The present invention provide a compound of the formula (I) wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R 1 and R 2 are the same or different and each represents a hydrogen atom, etc.; R 3 represents a hydrogen atom, etc.; R 4 and R 5 are the same or different and each represents a hydrogen, etc.; R 6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.

  本发明提供了一种化合物(I)的公式，其中环A代表一种芳香环，可选地具有取代基; B、Y和Ya相同或不同，每个代表一种键等; R1和R2相同或不同，每个代表一个氢原子等; R3代表一个氢原子等; R4和R5相同或不同，每个代表一个氢等; R6代表一种吲哚基，可选地具有取代基; Z和Za相同或不同，每个代表一个氢原子等; 或其盐或前药，具有生长抑素受体结合抑制活性，并用于预防和/或治疗与生长抑素相关的疾病。